V Bryan Lawlis Sells 3,750 Shares of BioMarin Pharmaceutical Inc. (BMRN) Stock
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director V Bryan Lawlis sold 3,750 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $88.84, for a total transaction of $333,150.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Shares of BioMarin Pharmaceutical Inc. (NASDAQ BMRN) opened at $90.27 on Friday. BioMarin Pharmaceutical Inc. has a 52 week low of $80.10 and a 52 week high of $100.51. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.81 and a current ratio of 4.91. The company has a market cap of $15,862.12, a P/E ratio of -100.30 and a beta of 1.82.
BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Thursday, October 26th. The biotechnology company reported ($0.07) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. BioMarin Pharmaceutical had a negative net margin of 12.45% and a negative return on equity of 4.60%. The business had revenue of $334.18 million for the quarter, compared to analysts’ expectations of $347.38 million. During the same period in the prior year, the firm earned $0.02 earnings per share. BioMarin Pharmaceutical’s revenue was up 19.4% compared to the same quarter last year. analysts anticipate that BioMarin Pharmaceutical Inc. will post -0.64 EPS for the current fiscal year.
A number of research analysts have recently commented on BMRN shares. Goldman Sachs Group reaffirmed a “buy” rating and set a $129.00 price objective on shares of BioMarin Pharmaceutical in a research report on Friday, October 6th. Royal Bank of Canada started coverage on shares of BioMarin Pharmaceutical in a research report on Thursday, September 14th. They set a “sector perform” rating and a $93.00 price objective for the company. Wedbush reaffirmed a “neutral” rating and set a $108.00 price objective on shares of BioMarin Pharmaceutical in a research report on Wednesday, November 15th. JPMorgan Chase & Co. set a $131.00 price objective on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a research report on Monday, November 27th. Finally, BidaskClub raised shares of BioMarin Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 16th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $112.44.
COPYRIGHT VIOLATION NOTICE: “V Bryan Lawlis Sells 3,750 Shares of BioMarin Pharmaceutical Inc. (BMRN) Stock” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/01/06/v-bryan-lawlis-sells-3750-shares-of-biomarin-pharmaceutical-inc-bmrn-stock.html.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Stock Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related stocks with our FREE daily email newsletter.